ArticlePloS one2012
Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03408093 (Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
Who cites it
17 citing papers in PubMed.
- Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon β.BMC neurology · 2014Trial
- Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Adherence, Persistence, Switching and Costs of Injectable and Oral Therapies for Multiple Sclerosis. Real Life Analysis Over 6 Years of Treatment.Hospital pharmacy · 2024Article
- Treatment satisfaction with disease-modifying therapy is the only predictor of Adherence among multiple sclerosis patients from Upper Egypt.Scientific reports · 2024Article
- Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain.Patient preference and adherence · 2023Article
- Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis.Therapeutic advances in neurological disorders · 2021Article
- Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database.Frontiers in neurology · 2021Article
- Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study.Journal of neurology · 2020Article
- Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain.Patient preference and adherence · 2019Article
- Impact of fampridine on quality of life: clinical benefit in real-world practice.European journal of hospital pharmacy : science and practice · 2018Article
- PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.International journal of technology assessment in health care · 2018Article
- Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.Patient preference and adherence · 2017Article
- Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by RebismartPatient preference and adherence · 2017Article
- Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.The patient · 2016Article
- Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis.PloS one · 2016Article
- Article
- Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis.International journal of MS careArticle
Corrections and comments
- Erratum issuedAgüera, Javier [corrected Agüera, Eduardo]; Millán-Pascual, Javier [corrected to Millán-Pascual, Jorge]Argente, Javier [correced to Argente, Joaquin]
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of treatment in multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFβ-1b in patients suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice. METHODOLOGY/PRINCIPAL
findingsThis was an observational, retrospective, cross-sectional study including 120 Spanish patients with MS under INFβ-1b treatment. Therapeutic adherence was assessed with Morisky-Green test and with the percentage of doses received. The proportion of adherent patients assessed by Morisky-Green test was 68.3%, being indicative of poor adherence. Nevertheless, the percentage of doses received, which was based on the number of injected medication, was 94.3%. The main reason for missing INFβ-1b injections was forgetting some of the administrations (64%). Therefore, interventions that diminish forgetfulness might have a positive effect in the proportion of adherent patients and in the percentage of doses received. In addition, age and comorbidities had a significant effect in the number of doses injected per month, and should be considered in the management of adherence in MS patients. CONCLUSION/SIGNIFICANCE: Among all the available methods for assessing adherence, the overall consumption of the intended dose has to be considered when addressing adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.